| ALMS |
ALUMIS INC. |
Foresite Labs Fund I, L.P. |
10% Owner
|
2025-11-21 |
P - A |
72,212 |
7.38 |
532,924.56 |
2,614,215 |
| ALMS |
ALUMIS INC. |
Foresite Labs Affiliates 2021, LLC |
10% Owner
|
2025-11-21 |
P - A |
72,212 |
7.38 |
532,924.56 |
2,614,215 |
| FSSL |
FS Specialty Lending Fund |
Forman Michael C. |
Director
Officer
|
2025-11-21 |
P - A |
10,000 |
13.27 |
132,700.00 |
76,824 |
| ARDX |
ARDELYX, INC. |
Foster Eric Duane |
|
2025-11-21 |
S - D |
5,814 |
5.54 |
32,191.54 |
295,684 |
| FOX |
Fox Corp |
MURDOCH KEITH RUPERT |
Other
|
2025-11-21 |
S - D |
100,000 |
59.26 |
5,926,000.00 |
1,100,862 |
| REXR |
Rexford Industrial Realty, Inc. |
Frankel Michael S. |
Director
Officer
|
2025-11-21 |
C - A |
80,250 |
0.00 |
0.00 |
640,656 |
|
Rexford Industrial Realty, Inc. |
Frankel Michael S. |
Director
Officer
|
2025-11-21 |
M - D |
80,250 |
0.00 |
0.00 |
532,871 |
|
Rexford Industrial Realty, Inc. |
Frankel Michael S. |
Director
Officer
|
2025-11-21 |
M - A |
80,250 |
0.00 |
0.00 |
80,250 |
|
Rexford Industrial Realty, Inc. |
Frankel Michael S. |
Director
Officer
|
2025-11-21 |
C - D |
80,250 |
0.00 |
0.00 |
0 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
A - A |
925,000 |
0.00 |
0.00 |
925,000 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
D - D |
155,090 |
0.00 |
0.00 |
0 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
A - D |
155,090 |
0.00 |
0.00 |
155,090 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
D - D |
23,786 |
0.00 |
0.00 |
0 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
A - A |
23,786 |
0.00 |
0.00 |
23,786 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
D - D |
37,296 |
0.00 |
0.00 |
0 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
A - A |
37,296 |
0.00 |
0.00 |
37,296 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
D - D |
45,000 |
0.00 |
0.00 |
0 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
A - A |
45,000 |
0.00 |
0.00 |
45,000 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
D - D |
20,000 |
0.00 |
0.00 |
0 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
A - A |
20,000 |
0.00 |
0.00 |
20,000 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
D - D |
117,000 |
0.00 |
0.00 |
0 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
A - A |
117,000 |
0.00 |
0.00 |
117,000 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
D - D |
150,000 |
0.00 |
0.00 |
0 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
A - A |
150,000 |
0.00 |
0.00 |
150,000 |
|
Xilio Therapeutics, Inc. |
Frankenfield Christopher James |
|
2025-11-21 |
D - D |
300,000 |
0.00 |
0.00 |
0 |